Adaptive Biotechnologies (NASDAQ:ADPT) used a presentation at the J.P. Morgan healthcare conference to outline growth drivers for its clonoSEQ minimal residual disease (MRD) franchise and to describe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback